The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer-Reference-Cited by-同舟云学术

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer

Published:2018-08 Issue:2 Volume:200 Page:344-352
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Ryan Charles J.¹,Crawford E. David²,Shore Neal D.³,Underwood Willie⁴,Taplin Mary-Ellen⁵,Londhe Anil⁶,Francis Peter St. John⁶,Phillips Jennifer⁶,McGowan Tracy⁶,Kantoff Philip W.⁷

Affiliation:

1. Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California

2. University of Colorado Cancer Center, Aurora, Colorado

3. Carolina Urologic Research Center, Myrtle Beach, South Carolina

4. Roswell Park Cancer Institute, Buffalo, New York

5. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

6. Janssen Scientific Affairs, LLC, Horsham, Pennsylvania

7. Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference20 articles.

1. Zytiga package insert,2018

2. Abiraterone in metastatic prostate cancer without previous chemotherapy. COU-AA-302 Investigators;Ryan;N Engl J Med,2013

3. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

4. Apalutamide treatment and metastasis-free survival in prostate cancer;Smith;N Engl J Med,2018

5. PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC);Hussain;J Clin Oncol,2018

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors for non‑metastatic castration‑resistant prostate cancer treated with androgen receptor signaling inhibitors;Molecular and Clinical Oncology;2024-08-08

2. Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States;Future Oncology;2024-07-29

3. Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy;Cancers;2024-07-26

4. Novel treatment strategies to overcome resistance in prostate cancer;Therapy Resistance in Prostate Cancer;2024

5. The efficacy and safety of androgen receptor signaling inhibitors in patients with non-metastatic castration resistant prostate cancer;2023-11-29